Summary The normal growth, development and function of an organism requires precise and co-ordinated control of gene expression. A major part of this control is exerted by regulating messenger RNA (mRNA) production and involves complex interactions between an array of transcriptionally active proteins and specific regulatory DNA sequences. The combination of such proteins and DNA sequences is specific for given gene or group of genes in a particular cell type and the proteins regulating the same gene may vary between cell types. In addition the expression or activity of these regulatory proteins may be modified depending on the state of differentiation of a cell or in response to an external stimulus. Thus, the differentiation of embryonic cells into diverse tissues is achieved and the mature structure and function of the organism is maintained. This review focusses on the role of perturbations of these transcriptional controls in neoplasia. Deregulation of transcription may result in the failure to express genes responsible for cellular differentation, or alternatively, in the transcription of genes involved in cell division, through the inappropriate expression or activation of positively acting transcription factors and nuclear oncogenes. Whether the biochemical abnormalities that lead to the disordered growth and differentiation of a malignant tumour affect cell surface receptors, membrane or cytoplasmic signalling proteins or nuclear transcription factors, the end result is the inappropriate expression of some genes and failure to express others. Current research is starting to elucidate which of the elements of this complicated system are important in neoplasia.
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The appearance and behaviour of cancer cells is a consequence of failure of normal regulation of expression of genes involved in cell growth and differentiation. There is inappropriate production of growth factors or growth factor receptors (Roberts & Sporn, 1985) , the expression or loss of surface antigens, such as HLA molecules (Bernards, 1987) , of structural proteins and of enzymes and excessive and uncoordinated cell replication. Since all somatic cells have the same complement of DNA, mechanisms are necessary to allow differential expression of proteins by the various cell types and also by the same cell type at different times, for example, in response to external stimuli or during the process of growth and development.
Transcription is the process of copying a part of the DNA template carrying the genetic code into messenger RNA (mRNA). This is then modified and travels to the cytoplasm, where it is translated into the amino acid sequence of the encoded protein. Regulation of transcription is of fundamental importance in the control of gene expression during such diverse events as the development of body segments by flies (Akam, 1987; Scott & Carroll, 1987) , neurogenesis in worms (Finney et al., 1988) and for muscle differentiation (Davies et al., 1990) , B-lymphocyte-specific immunoglobulin production (Lenardo et al., 1987) and the response to steroid hormones in mammals (Beato, 1989; Evans, 1988) . Evidence is now accumulating that transcriptional deregulation is equally important in the process of neoplasia.
How transcription is regulated
Tissue specific gene expression
In eukaryotic organisms, mRNA transcription from the DNA template requires both the general transcriptional machinery, including RNA polymerase II (pol II) and the general transcription factors TFIIA-F, and proteins (transacting factors) which specifically recognise short DNA sequences (cis-acting elements) in the non-coding region of the gene (Ptashne, 1986; Dynan & Tjian, 1985) . These sequences may be in the DNA immediately preceding (upstream of) the transcription start site, where they constitute the promoter necessary for accurate and efficient initiation of transcription, but may also lie several thousand bases upstream or even within introns or downstream of the gene, forming enhancers elements, which modulate promoter function (Maniatis et al., 1987) . Since pol II and the general factors are necessary for the transcription of most, if not all, active protein coding genes, differential regulation of genes is determined by the factors interacting with specific cis-acting elements. Thus, the combination of proteins controlling the transcription of an individual gene in a particular cell type depends firstly, upon which cis-acting elements are present in the promoter and enhancer regions of the gene in question and secondly, upon which trans-acting factors are expressed and active within the nucleus (Figure 1 ). In a simple system, tissue-specific expression of a set of genes could be achieved by the production in the tissue of an active transcription factor capable of interacting with a cis-acting element shared by those genes. However, the same cis-acting element may be present in the regulatory region of different genes which are not coordinately expressed (Johnson & McKnight, 1989) and in addition several factors capable of recognising the particular element may be present in the same cell (Dorn et al., 1987; Chodosh et al., 1988; Raymondjean et al., 1988; Cox et al., 1988) . Regulatory specificity is maintained by varying the context in which the cis-acting element occurs; the relative affinity of the factors for the core recognition site (cognate sequence) may be influenced by flanking DNA sequences, whilst their activity may be significantly modulated by proteinprotein interactions with other sequence-specific DNA binding proteins (McKnight & Tjian, 1986) . A major refinement of this relatively simple system has been achieved in eukaryotic organisms by the evolution of families of transcription factors which bind to their cognate sequence as homodimers or as heterodimers (see below) with other family members, allowing the specific and flexible control of transcription required for normal cellular function (Smeal et al., 1989; Benbrook & Jones, 1990; Murre et al., 1989a) . duction pathways may be activated, resulting in alteration in the level of transcription of responsive genes (Maniatis et al., 1987) (Figure 2 ). This may be achieved via the production of new transcription factors, e.g. the de novo synthesis of factors which increase transcription from interferon genes in response to viral infection (McDonald et al., 1990; Miyamoto et al., 1988) . Alternatively, the binding or transcriptional activity of factors already present within the cell may be modulated. This may be brought about either by covalent modification, e.g. the activation of cAMP-responsive transcription factors of the cyclic AMP response element binding protein (CREB) family by protein kinase A-mediated phosphorylation (Mellon et al., 1989) , or otherwise by the induction of conformational change, as occurs when a ligand binds to one of the steroid hormone receptors (which are transcription factors). This results in dissociation from the receptor of an inhibitory protein and enables it both to bind to its specific DNA recognition sequence and to activate transcription (Beato, 1989; Green & Chambon, 1988 (Akam, 1987; Scott & Carroll, 1987; Gehring, 1987) . Proteins with close structural similarity in man and mouse also show distinct domains of expression and some appear to define regional boundaries in the early development of the central nervous system and mesoderm (Manley & Levine, 1985; Graham et al., 1989) .
Transcription factor families share structuralfeatures As the genes for various transcriptional factors have been isolated it has become clear that the proteins they encode can be grouped together on the basis of shared structural features. This homology is particularly marked in the domains responsible for binding to DNA and for the formation of homo-or heteromeric complexes. In these regions the amino acid sequence may show a high degree of conservation between proteins which are, elsewhere, largely dissimilar. Relatively minor differences in these areas, for example single amino acid changes, can change the DNA-binding specificity of a protein, either directly, or by altering the repertoire of other proteins with which it can form complexes.
differentiates CELL PRE-Z Two structures, the basic-helix-loop-helix (bHLH) and the leucine zipper, involved in dimer/multimer formation, are now quite well characterised and show some similar features. The bHLH motif was originally identified as a region required for dimerisation and DNA binding in the E12 and E47 transcription factors that are involved in immunoglobulin gene expression, in the muscle specific factor, MyoD and in the myc oncoproteins (Murre et al., 1989a) . It has since been identified in a wide variety of other proteins with diverse functions ranging from phosphatase gene regulation in yeast (Ogawa & Oshima, 1990) to neuronal development in Drosophila (Vilares & Cabrera, 1987) . The bHLH motif is composed of a 13 amino acid region containing several highly conserved basic amino acids, immediately N-terminal to two a-helices which are separated by a loop of variable length ( Figure 4a ). The helices have hydrophobic amino acids positioned along one face (hydrophobic amphipathic helix) (Figure 4d) and it is through these residues that the helices of one protein molecule are thought to interact with those of another to form homo-or heteromeric complexes. The helices do not directly contact the DNA, but the formation of multimers enables the protein to bind to its cognate sequence via the adjacent basic region. A second structure, the leucine zipper, is composed of a single hydrophobic amphipathic a-helix, with leucines on its hydrophobic face, through which related proteins can interact ( Figure 4c ) (Landschulz et al., 1988a; Kouzarides & Ziff, 1989) . As with the bHLH proteins, this helix may be positioned a specific distance from a cluster of basic amino acids which mediate DNA-binding, forming the bZip domain (Vinson et al., 1989) . There is a growing family of bZip transcription factors several of which are capable of combining as stable and functionally active homo-and heterodimers ( Figure 4b ) (Smeal et al., 1989; Kouzarides & Ziff, 1989; Hai et al., 1989) . A separate group of proteins, which includes the myc proteins, and transcription factors AP-4 and USF, contain both a bHLH motif and a leucine zipper (Hu et al., 1990; Gregor et al., 1990) . In these proteins the leucine zipper, which is required for function, is positioned C-terminal to the bHLH, and probably cooperates with it in the formation of homo-and heteromeric complexes.
Two other frequently recurring motifs, the zinc finger and the homeobox, have been shown to be directly responsible for sequence specific DNA-binding by families of transcription factors. The zinc finger was first described in the transcription factor TFIIIA from the toad Xenopus laevis, where it occurs nine times (Miller et al., 1985; Brown et al., 1985) .
Two pairs of appropriately spaced cysteine or cysteine and histidine residues form a complex with a zinc ion resulting in Figure 3 Differentiation. In the immature pre-Z cell, gene I is inactive due to sequestration of factor 'b' by its inhibitor 'Ib', whilst the activator 'c' of gene 2 is not expressed. The growth-related gene, 3, is very active due to factors r' and 'g'. When the cell differentiates, genes I and 2 function due to loss of 'Ib' expression, allowing dimerisation of 'b', and production of 'e', respectively.
The absence of 'f' and inactivation of 'g' severely reduces transcription of gene 3. the formation of a 'finger' by the intervening amino acids ( Figure 5 ). The finger structure has been demonstrated by X-ray crystallography (Diakun et al., 1986) and the requirement for zinc shown by the loss of DNA binding in the presence of ion chelators (Kadonaga et al., 1987) . Up to at least 13 zinc fingers can be present in a single protein, as in the testis determining factor, involved in sex determination (Page et al., 1987) . In some zinc finger proteins all the fingers may be identical, but in others they appear to subserve different functions. For example, Green and Chambon (1987) have showed that in members of the steroid hormone receptor family, which all have two fingers, one provides DNA-binding specificity, whilst the other stabilises the protein-DNA complex, probably by contacting the phosphate backbone of the DNA. The homeobox, was originally identified as a conserved element in a number of genes involved in segmentation in Drosophila (Gehring, 1987) , but it has since been found in proteins with various functions from many phyla. Predictions of the structure of the homeobox based on its amino acid sequence suggested it would form three stretches of a-helix separated by short flexible spacers (Laughon & Scott, 1984; Shepard et al., 1984) . This motif, the helix-turn-helix (HTH), was first described in bacterial transcriptional repressors (Pabo & Sauer, 1984) . X-ray crystallography of homeodomain-DNA co-crystals has confirmed this structure and shown that, as with the prokaryotic HTH, one of the helices lies in the major groove of the DNA double helix, contacting the bases, whilst the others are positioned perpendicular to this, and predominantly contact the phosphate backbone (Kissinger et al., 1990) . In the POU domain, found in a related group of proteins (including Pit-l, Oct, and Unc 86), a homeobox and a 'POU-specific' domain are separated by a short spacer . The POU-homeodomain, 
tional regulation may also be important in neoplasia. A number of possible mechanisms might be envisaged ( Figure  6) unlike the pure homeobox which is sufficient for DNA binding on its own, requires an appropriately placed POU-specific domain to bind its cognate sequence efficiently (Martin, 1970) . Later it was discovered that viral oncogenes are modified forms of normal cellular genes, so-called proto-oncogenes, the products of which are involved in the control of cell growth and proliferation. Inappropriate expression of these genes results in transformation of cells in culture.
Many proto-oncogene products are growth factors, surface membrane receptors and cytoplasmic or membrane bound proteins normally involved in the receipt and transduction of growth signals (for review see, Varmus & Bishop, 1986) . A number, including myc, myb, fos, jun and Erb-A, are found in the nucleus, where it has been proposed that they provide the final stage in the signalling pathway (Pawson, 1987) . Recent work has demonstrated that jun, fos, myb, Erb-A and probably myc are involved in transcriptional regulation.
The jun-fos story The first example of an oncogenic transcription factor was v-jun, the transforming gene of the chicken sarcoma virus ASV17 (Maki et al., 1987) . The amino acid sequence of the product of this gene was compared to other known proteins and part of it was found to be very similar to the DNAbinding domain of the yeast transcription factor, GCN4 . When the DNA-binding domain of GCN4 was replaced with the homologous region of v-jun, the chimLeric protein continued to function as a transcription factor (Struhl, 1988) , suggesting that the v-jun product would also bind to DNA. Its function, however, remained unknown.
AP-1 is a transcription factor (or family of factors) involved in mediating the transcriptional response to activation of protein kinase C. It recognises variations on the DNA sequence TGACT(C/A)A (A = adenosine, t = cytidine, G = guanosine, T = thymidine) (Lee et al., 1987; Angel et al., 1987) , which is very similar to the cognate sequence of GCN4 (ATGA(C/G)TCAT) (Hill et al., 1986 ). Monoclonal antibodies raised against different regions of v-jun were shown to precipitate AP-l, but not other transcription factors, from nuclear extracts (Box et al., 1988) and subsequently the peptide sequence of the 47 kD protein in purified API preparations was shown to be identical to c-jun (Angel et al., 1988) . When compared to c-jun, v-jun shows two amino acid changes in the DNA-binding domain and a deletion towards its N-terminus, in the region responsible for transcriptional activation . The deletion removes part of the protein required for interaction with a cell-type specific repressor factor, possibly freeing the viral protein from normal control and thus rendering it oncogenic (Baichwal & Tjian, 1990 (Curran et al., 1984) . Immune precipitation experiments demonstrated the presence of c-fos in complexes binding to the AP-1 sequence (Distel et al., 1987) . A number of other proteins were co-precipitated as a result of interaction with fos, the most abundant of which was c-jun/AP-1 (Sassone- Corsi et al., 1988; .
Analysis of the protein structure of fos and jun revealed that each has a leucine zipper, which enables protein-protein interactions necessary for DNA binding (Kouzarides & Ziff, 1989; Vinson et al., 1989 Figure 6 Transcription and transformation. Cell X. Gene I is not expressed due to mutation (*) of the activator domain of 'b', whilst transcription of gene, 3, is activated as a result of (i), production of a chimaeric factor, due to a chromosomal translocation, API sites and activate transcription (Smeal et al., 1989) . V-fos differs from c-fos in its C-terminal 49 amino acids as a result of a deletion which alters the reading frame of the viral gene (van Beveren et al., 1983 (Land et al., 1983) . However, the function of the myc proteins has remained a mystery, for although they could be shown to bind non-specifically to DNA (Abrams et al., 1982) , little more was known. Recently, however, the myc proteins were shown to possess the basic/helix-loop-helix (bHLH) motif. This domain is also found in a number of known and putative transcription factors involved in differentiation and tissuespecific gene expression (Davis et al., 1990; Murre et al., 1989a, b) . To the C-terminal side of the bHLH domain, myc also has a leucine zipper domain, similar to that present in fos and jun, which has also been shown to be necessary for the formation of myc multimers, but which also may enable interaction with other proteins (Dang et al., 1989) . These data suggest strongly that myc functions, at least in part, as a transcription factor and that it has the potential for interaction with a wide variety of other proteins.
c-myb
The oncogene v-myb, carried by two chicken retroviruses, avian myeloblastosis virus and E26, is a truncated version of the cellular proto-oncogene c-myb (Gonda & Bishop, 1983;  Klempnauer et al., 1983) which encodes a nuclear protein of MW 75-80 kD (Klempnauer et al., , 1984 (Klempnauer et al., , 1986 expressed in immature, but not in differentiated haematopoietic cells (Duprey & Boettiger, 1985) . When chicken bone marrow cells are transformed with v-myb their differentiation is blocked and they have the phenotype of myeloid precursors (Gazzolo et al., 1979) , whilst overexpression of c-myb prevents the induction of differentiation of cultured erythroleukaemia cells (McMahon et al., 1988) . Both v-and c-myb bind specifically to the sequence PyAACG/TG (Py = pyrimidine) and activate transcription from reporter genes (i.e. foreign genes with assayable products) linked in cis to this motif (Howe et al., 1990; Weston & Bishop, 1989; Sakura et al., 1989) . A cellular gene, miml, encoding a promyelocyte specific secretory protein, which is activated by myb, has been identified (Ness et al., 1989 ). Very recently, it has been shown that phosphorylation of certain serine residues in c-myb, by casein kinase II, prevents it from binding to DNA. The region of c-myb containing these residues is deleted from v-myb and activated c-myb genes . Transformation is probably the result of expression of a myb protein which cannot be prevented from binding to DNA and which thus inappropriately activates transcription from genes responsible for cell growth.
Other nuclear oncogenes At least five other known viral oncogenes encode proteins which are, or are extremely likely to be, deregulated transcription factors. The best characterised of these is v-ErbA, one of the transforming genes of the avian erythroblastosis virus, which encodes a truncated thyroid hormone receptor (Sap et al., 1986; Weinberger et al., 1986) , a relative of the steroid hormone receptors (see above) (Evans, 1988;  Thompson & Evans, 1989) . As a result of deletion of part of the C-terminus of the normal receptor, the viral ErbA protein is unable to bind thyroid hormone. It does, however, bind correctly to thyroid hormone-responsive DNA elements, functioning as a constitutive repressor of thyroid hormone responsive genes and competitive antagonist of the normal thyroid hormone receptor/ligand complex (Damm et al., 1989) , suggesting that it may transform erythroblasts by blocking thyroid hormone-mediated differentiation.
v-ets is a second oncogene present in the genome of avian leukosis virus, E26, which also bears v-myb and is necessary for it to induce erythroblastosis (Leprince et al., 1983; Nunn et al., 1983; Nunn & Hunter, 1989) . The product of the chicken proto-oncogene, c-ets-l, from which it is derived, is a member of a family of nuclear phosphoproteins of short half-life, expressed predominantly by proliferating cells (Fujiwara et al., 1988a, b; Pognonec et al., 1989) . Ets and related proteins are also present in insects and other vertebrates (Pribyl et al., 1988; Reddy et al., 1987; Rao et al., 1989 ) and all share a highly conserved region of basic amino acids at the C-terminus . c-ets-l binds specifically to a cis-acting element in the long terminal repeat (LTR) of the Moloney murine sarcoma virus (Gunther et al., 1990) and to a closely related sequence, PEA3, in the polyoma virus enhancer. It activates transqiption from these sequences and, in the polyoma enhancer, functions cooperatively with members of the fos-jun family which bind to an adjacent API site (Wasylyk et al., 1990 ). In addition, juxtaposed API and PEA3 sites are found in the promoter of a number of oncogene-responsive genes (Wasylyk et al., 1989) . The avian retrovirus ReVT, which causes rapidly progressive lymphoid tumours in birds, carries the v-rel oncogene (Stephens et al., 1983) . Its product is found in the nucleus of some cells and in the cytoplasm of others (Gilmore & Temin, 1988) . The proto-oncogene c-rel has recently been shown to be related to, and capable of participating in heterotetrameric complexes with one subunit of NFjcB, a multifunctional transcription factor, and dorsal, a Drosophila protein involved in dorsal/ventral axis determination (Kieran et al., 1990; Ghosh et al., 1990) . NFicB is produced as a large non-DNA binding precursor and its activity may be regulated partly through the rate of cleavage of this molecule to a smaller form. However sequestration in the cytoplasm by the related protein IKB, which cannot bind to DNA, is probably more important (Bauerle & Baltimore, 1988 ). It appears that, unlike c-rel, v-rel cannot activate transcription, but it retains the ability to interact with other related proteins. Thus it may interfere with the normal equilibrium between active and inactive complexes and lead to aberrant transcriptional regulation.
The nuclear oncogenes v-ski and v-maf are less well characterised than those described above. V-ski was isolated from an avian leukosis virus in culture and the protein it encodes has several features which suggest it may be a transcription factor (Stavnezer et al., 1989) . The function of the c-ski proto-oncogene from which it is derived is unknown, however transformation of quail embryo cells with v-ski causes them to undergo myogenic differentiation suggesting a rela-tionship to the MyoD family of myogenic proteins (Davis et al., 1990; Colmenares & Stavnezer, 1989 ). V-maf, which causes naturally occurring fibrosarcomas in fowl, shows regions of structural similarity to the fos and jun oncogenes having both a leucine zipper motif (Nishizawa et al., 1989) and an adjacent domain of basic amino acids which fits the consensus sequence of the bZip proteins (Vinson et al., 1989) . In addition it has stretches of uninterrupted glycine and histidine residues, a single polyglycine sequence being a feature of the leucine zipper transcription factor, C/EBP (Landschulz et al., 1988b) .
Abnormalities of transcription factors in human tumours
Whilst the identification and characterisation of oncogenic transcription factors has told us much about the mechanisms of transcriptional control and deregulation, to date only the expression of myc proto-oncogenes, whose transcriptional role is still not finally proven, has been shown to be abnormal in human tumours. However, some recent work has demonstrated more clearly the direct role of other transcription factors in human neoplasia (Table I) .
Pre-B ALL and helix-loop-helix proteins
The tumour cells of 30% of patients with childhood pre B-Acute Lymphoblastic Leukaemia (pre B-ALL) carry the translocation t(1:19) (q23:pl3.3) (Williams et al., 1984) . Two groups investigating the translocation breakpoint have shown that a chimwric gene is produced, from which a potentially functional transcription factor is synthesised (Nourse et al., 1990; Kamps et al., 1990) . The N-terminal part of the novel protein is contributed by the E2a gene from chromosome 19, encoding the myc-related proteins E12 and E47, which normally stimulate constitutive transcription from the kappa immunoglobulin promoter in B-cells (Murre et al., 1989b; Moss et al., 1988) . The part of the protein retained in the chimwric factor is the potent transcriptional activator domain. The C-terminus, encoded by part of a gene on chromosome 1, normally inactive in pre-B lymphocytes, is the homeodomain of a newly identified factor of unknown function, designated prl. Many of the proteins sharing this structural feature are involved in developmental and tissue-specific regulation of gene expression (Gehring, 1987; Ingraham et al., 1988; Scheidereit et al., 1988; Johnson & Hirsh, 1990) .
Thus, the result of the pre B-ALL translocation is a protein which may be capable of strongly activating a gene or group of genes involved in the control of normal differentiation and not normally expressed at this stage of lymphocyte ontogeny. Two additional bHLH proteins, relatives of E12/E47, have been implicated in different forms of acute leukaemia. One, SCL, was identified as the protein encoded by the gene on chromosome 1 involved in the breakpoint of the translocation, t(l:14) (p33;ql 1.2) in a primitive acute leukaemia capable of both myeloid and lymphoid differentiation. The normal SCL gene is expressed by haematopoietic stem cells and myeloid and T lymphocyte precursors (Begley et al., 1989) whilst an aberrant mRNA, including at its 3' end part of the T-cell receptor (TCR) 6 chain gene, is produced by tumour cells. The same gene is also involved in the translocation t(l :14) (p32;ql 1) in a small group of T-cell acute lymphoblastic leukaemias (T-ALL) (Chen et al., 1990) . In these malignant cells the SCL gene is fused to the 5' part of the TCR 6 gene and thus it may be expressed under the control of an inappropriate promoter. The second protein, designated Lyl-1, is closely related to SCL and is expressed in another subset of T-ALLs, in a truncated form, as the result of a t(7:19) translocation which juxtaposes its gene to that of the TCR P chain (Mellentin et al., 1989) . Further study of these proteins should give valuable insight into the role of transcription in normal haematopoietic development and in neoplasia.
Wilms' tumour and the zinc finger proteins Gross cytogenetic deletions and rearrangements affecting chromosome 11 (band p1 3) are common finding in hereditary and some sporadic Wilm's tumours. The gene inactivated by these changes encodes a protein (the WT protein) with four 'zinc fingers' near to its C-terminus suggesting that it is a transcription factor (Call et al., 1990; Gessler et al., 1990) . Its N-terminus is rich in both proline and glutamine residues, amino acids occurring frequently in the activation domains of some other transcription factors (Mermod et al., 1989; Tanaka & Herr, 1990 ). The gene is strongly expressed in the embryonic kidney and its product appears to be required for the switch from mesodermal to epithelial differentiation which occurs in the developing urogenital sysem (PritchardJones et al., 1990) . The mechanism by which homologous deletion or rearrangement of the WT gene leads to the uncontrolled proliferation of nephroblasts is unknown, but one might speculate that the normal WT protein stimulates their differentiation into nephrons and its inactivation allows continued growth and division. This is supported by the inability of nephroblastoma cells transfected with a normal chromosome 11, to form tumours, but more definitive work is awaited (Weissman et -a., 1987) .
In acute promyelocytic leukaemia (APL; FABM3), tumour cells carry the translocation t(15:17) (q22; qll.2-ql2) in approaching 100% of cases (Sheer et al., 1984) . The chromosome 17 breakpoint has been characterised in a number of cases and shown to fall in the first intron of the retinoic acid receptor a (RARA) gene (Borrow et al., 1990) . The product of this gene is related to the steroid hormone receptors, and as a result of the translocation, the first exon, which encodes the transcription activation domain, is separated from the DNA-binding and ligand-binding domains, which become part of the derivative chromosome 15. The gene to which they are attached awaits characterisation, but as with pre-B ALL the resultant fusion protein is likely to be of great importance in understanding the behaviour of the tumour cells and probably explains the response of APL to retinoic acid.
Other zinc finger proteins have also been implicated in neoplasia. The gene GLI, on chromosome 12, is amplified in a proportion of human malignant gliomas . Evidence suggests that the GLI protein may be involved in normal development as it is most closely related to the 'Kruppel' zinc finger proteins (Kinzler et al., 1988) involved in Drosophila segmentation (Schuh et al., 1986; Chowdhury et al., 1987) and is produced by embryonal carcinoma cells but not by adult tissues.
The translocation, t(I 1:14) (p1 5;ql 1), present in a group of T-ALL activates the gene, ttg, (McGuire et al., 1989; Boehm et al., 1988) , which encodes a zinc finger protein normally expressed in the developing nervous system and in certain regions of the mature brain (Greenberg et al., 1990) . It is likely that that proteins described above are not the only developmentally regulated transcription factors with a role in transformation.
Future prospects In addition to yielding a greater understanding of the malignant process, the study of transcription may also provide advances in the diagnosis, assessment of prognosis and treatment of cancer. Whilst the inappropriate expression or repression of various genes may underlie the behaviour and histological appearance of a malignant tumour, in reaching a diagnosis the pathologist relies, to a great extent, upon the persistence of some features of differentiation in the tumour cells. For example, the identification of cytokeratins in epithelial tumours; of melanin and neuroendocrine markers in melanomas; of desmin, myoglobin and the cross striations produced by the contractile machinery of skeletal muscle in rhabdomyosarcomas; and of leucocyte common antigen in lymphomas frequently aids assessment. Unfortunately, these Refs: 'Nourse et al., 1990; 2Kamps et al., 1990; 3Begley et al., 1989; 4Chen et al., 1990; 5Mellentin et al., 1989; 6McGuire et al., 1989; 7Shima et al., 1986; 8Call et al., 1990; 9Gessler et al., 1990; '0Borrow et al., 1990; '2Wong et al., 1987; 3Erikson et al., 1983; '4Nishikura et al., 1983. markers are produced in different amounts by individual tumours of the same type and in a proportion no evidence of differentiation can be identified, making classification and therefore rational treatment difficult. The identification of tissue-specific transcription factors in cancer cells could offer a considerable advance in tumour diagnosis. As described above, it is likely that transcription factors are responsible for determining the line of differentiation undertaken by a cell and such factors must be expressed prior to the genes which they regulate. Already a number of proteins controlling muscle-specific gene expression, which cause differentiation of fibroblasts into skeletal muscle have been cloned (Davis et al., 1990; Miner & Wold, 1990; Braun et al., 1989; Braun et al., 1990; Wright et al., 1989; Rhodes & Konieckny, 1989) , whilst factors binding to HMW keratin promoters have been identified in keratinocytes (Lersch et al., 1989; Jiang et al., 1990) . In the future the demonstration of tissue-specific transcription factors within otherwise undifferentiated tumour cells may enable a correct diagnosis to be reached and thus appropriate chemotherapy to be given.
With regard to prognosis and treatment, assessment and manipulation of transcription factors is already commonplace in many centres; the oestrogen and progesterone receptor status of breast carcinomas is a routinely applied and valuable, prognostc indicator (DeSombre et al., 1979; Maynard et al., 1978) and administration of tamoxifen, a competitive oestrogen antagonist, is a standard treatment. When tamoxifen binds to the oestrogen receptor, dimerisation and DNA binding occur normally, but transcriptional activation is inhibited (Kumar & Chambon, 1988) . Thus oestrogen-mediated stimulation of growth-related genes is prevented. A similar situation is likely to result from the administration of anti-androgens, such as cyprotersone acetate, to patients with prostatic carcinoma. The treatment of lymphoma with corticosteroids may act via the glucocorticoid receptor either to suppress transcription from genes involved in cell division or to stimulate differentiation (Beato, 1989; Thompson, 1989) . In the future, as a greater understanding of the transcriptional machinery is gained, it is likely firstly, that other transcription factors will be identified whose production by a tumour will correlate with a better or a worse prognosis and secondly, that drugs will be developed which can interact with the transcriptional machinery to repress cell growth and division or stimulate differentiation of tumour cells. Whilst this is currently only speculation, transcription-related research should soon yield major dividends for cancer patients. 
